The main interest of the Zheng group is to develop clinically translatable technology platforms to combat cancer. Examples are:
- Porphysome nanotechnologyWe recently discovered porphysomes, the first-in-class, all organic and targetable nanoparticles with intrinsic multimodal photonic properties (Nature Materials, 2011). These 'one particle to rule them all' nanoparticles (editorial, Nature Methods, 2011) were identified by the Canadian Cancer Society as one of the top-ten breakthroughs in cancer research in 2011. They are self-assembled from porphyrin-lipid building blocks to form liposome-like nanoparticles (~100 nm diameter). The porphyrin packing density is so high (>80,000 per particle) that they absorb and convert light energy to heat with extremely high efficiency, making them ideal candidates for photothermal therapy and photoacoustic imaging. In addition, the large aqueous core of porphysomes could be loaded with drugs; upon porphysome bilayer disruption, fluorescence imaging could be enabled. Compared with any other photonic nanomaterials, porphysomes have considerably lower translational hurdles owing to their a) robust scale up following proven liposome technology, b) extremely low systemic toxicity, and c) biodegradable in vivo. Further, porphysomes can directly chelate metal ions thus unlocking their potential to go far beyond biophotonics (e.g., positron emission tomography (PET), magnetic resonance imaging (MRI) and radiation therapy). Together, the simple yet intrinsic multimodal nature of porphysomes not only confers high potential for clinical translation but also represents a novel principle for designing multifunctional nanoparticles.
- Lipoprotein-like nanoparticlesLipoprotein-like nanocarriers are a novel class of biocompatible, biodegradable and multifunctional nanoparticles based on chemically modified lipoproteins or artificially engineered lipoprotein mimetics. In particular, the ultra small HDL-like nanopaticles are capable of delivering therapeutic molecules (siRNA or drugs) directly into the cytosol of cancer cells thus bypassing the detrimental endosomal trapping for cancer therapeutics. DLVR Therapeutics, a new Ontario start-up company was recently created to commercialize this novel nanotechnology.
- Photodynamic molecular beaconsMolecular beacons are target-activatable probes that use the fluorescent resonance energy transfer principle to control their fluorescence emission in response to specific biological stimuli. We have extended this exclusive imaging utility to the concept of activatable photodynamic therapy. These therapeutic beacons usually comprise a disease-specific linker (e.g., peptides or oligonucleotides), a photosensitizer and a quencher. This configuration allows the photosensitizer's phototoxicity to be silenced until the specific linker-target interactions (e.g., protease-mediated linker cleavage or nucleic acid hybridization-induced linker opening). Thus, the beacons can achieve a very high level of PDT treatment selectivity by destroying only the targeted cancer cells, while leaving non-targeted (normal) cells unharmed.
Endocr Relat Cancer. 2019 Nov 01;:
Chest. 2019 Apr 26;:
Evaluation of novel imaging devices for nanoparticle-mediated fluorescence-guided lung tumor therapy.
Ann Thorac Surg. 2019 Feb 08;:
Stenosing tenosynovitis : Evaluation of percutaneous release with a specially designed needle vs. open surgery.
Orthopade. 2019 Jan 08;:
Study of the enantioselectivity and recognition mechanism of sulfhydryl-compound-functionalized gold nanochannel membranes.
Anal Bioanal Chem. 2018 Nov 19;:
Angew Chem Int Ed Engl. 2018 Jun 11;:
Specific and Direct Amplified Detection of MicroRNA with MicroRNA:Argonaute-2 Cleavage (miRACle) Beacons.
Angew Chem Int Ed Engl. 2017 Oct 23;56(44):13704-13708
Adv Drug Deliv Rev. 2017 04;113:97-121
Ann Thorac Surg. 2018 Oct 11;:
Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma.
Int J Oncol. 2018 Nov;53(5):2034-2046
Senior Scientist, Princess Margaret Cancer Centre
Associate Research Director, Princess Margaret Cancer Centre
Professor of Medical Biophysics, University of Toronto
Professor, Institute of Biomaterials and Biomedical Engineering, University of Toronto
Professor, Department of Pharmaceutical Sciences, University of Toronto
Full Member, Institute of Medical Science, University of Toronto
Scientist (Cross-Appointment), Joint Department of Medical Imaging, Mount Sinai Hospital, University Health Network, and Women’s College Hospital
Canada Research Chair in Cancer Nanomedicine, Tier I
Associate Editor, Bioconjugate Chemistry
Fellow, American Institute of Medical and Biological Engineering (AIMBE)